The possibilities for the design of new drug screening and development strategies
directed to a specific objective on the basis of genetic engineering of microorganisms
is discussed from two points of view. Firstly, results of work on genetic hybrids
of Streptomyces species for the production of new metabolites such as mederrhodin (1) and aloespanoarin
II (4) are described. Secondly, the enhanced production of known metabolites such
as tetracenomycin A2 (11) and tetracenomycin C (9) by recombinant Streptomyces species is considered. Mechanistic aspects of polyketide metabolism are included.
Microorganisms - polyketide metabolism - drug development -
Streptomyces species - genetic engineering